An industry in transition: Life Sciences Index 2026

The second edition of the Life Sciences Index highlights a sector undergoing transition amid rapidly shifting global dynamics. Drawing on insights from over 200 leaders across the world’s largest biopharma and medtech companies, the Index presents a comprehensive view of how innovation and growth priorities have evolved over the past two years. Overall, industry attractiveness has dipped from 75% to 71%, reflecting new market pressures and emerging constraints on traditional innovation pathways.

This year’s findings point to several defining trends: shifting global market attractiveness, a renewed emphasis on dealmaking as the primary engine of growth, accelerated AI adoption, and the continued rise of decentralised, patient centric models of care. At the same time, companies are reassessing their ESG priorities while contending with tariff driven changes to R&D and manufacturing strategies.

Download the Index to explore the data, trends and expert perspectives shaping the future of life sciences.